Tissue Diagnostics Market by Product (Antibodies, Kits, Slide Staining System, Tissue Processing System), Technology (ISH, IHC, Special Staining), Disease (Breast Cancer, NSCLC, Lymphoma), End User (Hospitals, Research Laboratories)-Global Forecast to 2025

組織診断の世界市場予測:製品別(抗体、キット、スライド染色システム、組織処理システム)、技術別(ISH、IHC、特殊染色)、疾患別(乳がん、NSCLC、リンパ腫)、エンドユーザー別(病院、研究所)

◆タイトル:Tissue Diagnostics Market by Product (Antibodies, Kits, Slide Staining System, Tissue Processing System), Technology (ISH, IHC, Special Staining), Disease (Breast Cancer, NSCLC, Lymphoma), End User (Hospitals, Research Laboratories)-Global Forecast to 2025
◆商品コード:MD 2349
◆調査・発行会社:MarketsandMarkets
◆発行日:2020年5月20日
◆ページ数:175
◆レポート形式:PDF / 英語
◆納品方法:Eメール(受注後24時間以内)
◆調査対象地域:グローバル
◆産業分野:医療機器
◆販売価格オプション(消費税別)
Single User(1名様閲覧)USD4,950 ⇒換算¥529,650見積依頼/購入/質問フォーム
Multi User (Five User)USD6,650 ⇒換算¥711,550見積依頼/購入/質問フォーム
Corporate License (全社内共有可)USD8,150 ⇒換算¥872,050見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※商品の納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。(振込先:三菱東京UFJ銀行/京橋支店/H&Iグローバルリサーチ株式会社)
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※ご購入後、レポートに記載の英語表現や単語の意味に関しましては無料でお答えいたします。(但し、対応範囲は弊社で判断)
※弊社H&Iグローバルリサーチ株式会社はMarketsandMarketsの日本における正規販売代理店です。

【レポートの概要】

MarketsandMarkets社は組織診断の世界市場が2020年34億ドルから2025年47億ドルまで、年平均6.5%成長すると予測しています。本調査レポートでは、組織診断の世界市場を詳細に調査・分析し、イントロダクション、調査手法、エグゼクティブサマリー、プレミアムインサイト、市場概要、製品別(消耗品、器具)、技術別(免疫組織化学(IHC)、現場ハイブリダイゼーション(ISH)、デジタル病理学&ワークフロー管理、特殊染色)、病気別(乳がん、胃がん、リンパ腫、前立腺癌、6非小細胞肺癌(NSCLC)、その他)、エンドユーザー別(病院、研究室、製薬会社、契約研究組織、その他)、地域別、競争状況、企業概要などを含め、ご提供いたします。
・イントロダクション
・調査手法
・エグゼクティブサマリー
・プレミアムインサイト
・市場概要
・組織診断の世界市場:製品別(消耗品、器具)
・組織診断の世界市場:技術別(免疫組織化学(IHC)、現場ハイブリダイゼーション(ISH)、デジタル病理学&ワークフロー管理、特殊染色)
・組織診断の世界市場:病気別(乳がん、胃がん、リンパ腫、前立腺癌、6非小細胞肺癌(NSCLC)、その他)
・組織診断の世界市場:エンドユーザー別(病院、研究室、製薬会社、契約研究組織、その他)
・組織診断の世界市場:地域別
・競争状況
・企業概要

“The global tissue diagnostic market size is projected to register a CAGR of 6.5% during the forecast period.”
The global tissue diagnostics market is expected to reach USD 4.7 billion by 2025 from USD 3.4 billion in 2020, at a CAGR of 6.5%. The growth in this market is driven by rising incidence of cancer, developing infrastructure for cancer diagnosis, the recommendation of cancer screening, availability of reimbursements, and increasing healthcare expenditure.

“The consumables segment is anticipated to grow at the fastest growth rate during the forecast period”
Based on product type, the tissue diagnostics market is segmented into instruments and consumables. The consumables segment is expected to grow at the highest growth rate during the forecast period. The large market share of this segment is driven mainly by their requirement in large numbers, cost-effectiveness, and ease of use. The increasing number of reagent rental agreements is also one of the major factors to drive the growth of the consumables market globally.

“The immunohistochemistry segment is estimated to grow at a rapid rate during the analysis period”
Based on the technology type, the tissue diagnostic market is segmented into immunohistochemistry, in situ hybridization, digital pathology and workflow, and special staining. The immunohistochemistry segment is estimated to register the highest CAGR during the forecast period. This can primarily be attributed to is increasing prevalence of chronic diseases across the globe, where this technology is mostly used in tissue diagnostics.

“Asia Pacific is estimated to register the highest CAGR during the study period”
Geographically, the tissue diagnostic market is dominated by North America and followed by Europe in 2019. However, the Asia Pacific region is estimated to grow at the fastest rate during forecast to period. Economic growth in the countries of this region, large population base, rising prevalence of chronic diseases, rising standard of living, growing demand for quality medical care, increasing healthcare spending, increasing government initiatives, and rising awareness regarding the use of tissue diagnostic tests, will drive the market in the region over the forecast period.

Breakdown of Profiles of Primary Participants:
• By Company Type: Tier 1: 32%, Tier 2: 44%, and Tier 3: 24%
• By Designation: C-level: 30%, Director-level: 34%, and Others: 36%
• By Region: North America: 40%, Europe: 28%, Asia Pacific: 20%, and the Rest of the World: 12%

The key players in the tissue diagnostic market include Roche (Switzerland), Danaher (US), Thermo Fisher Scientific (US), Abbott (US), Agilent Technologies (US), ABCAM (UK), Merck KGAA (Germany), BD (US), Hologic (US), Bio Rad (US), Biomeriux (France), Sakura Fientek Japan (Japan), BioSB (US), Biogenex (US), Cell Signaling Technology (US), Histoline Laboratories (Italy), Slee Medical GMBH (Germany), Amos Scientific PTY Ltd (Australia), Jinhua Yidi Medical Appliance Co.Ltd (China), Medite GMBH (Germany), Cellpath Ltd(UK), Dipath S.P.A. (Italy).
Research Coverage:
The report analyzes the tissue diagnostic market by product, technology, disease, end user, and region. Apart from comprehensive geographic product analysis and market sizing, the report also provides a competitive landscape that covers the growth strategies adopted by market players over the last three years. In addition, the company profiles include the product portfolios, developments, and strategies adopted by prominent market players to maintain and increase their shares in the market. Market research data, current market size, and forecast of future trends will help key market players and new entrants to make the necessary decisions regarding product offerings, geographic focus, change in strategic approach, and levels of output to remain successful in the market.
Key Benefits of Buying the Report:
This report will enable both established firms and new entrants/smaller firms to gauge the pulse of the market, which, in turn, will help these firms garner greater market shares. Firms purchasing the report can use any 1, or a combination of the below mentioned 5 strategies to increase their market shares.
The report provides insights on the following pointers:
• Market Penetration: Comprehensive information on the products of the top players in the tissue diagnostic market
• Competitive Assessment: In-depth assessment of the market strategies, geographic and business segments, and product portfolios of the leading players in the tissue diagnostic market
• Market Development: Detailed information about emerging markets.
• Market Diversification: Exhaustive information about new products, untapped geographies, recent developments, and investments in the tissue diagnostic market

【レポートの目次】

TABLE OF CONTENTS

1 INTRODUCTION (Page No. – 19)
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 MARKET SCOPE
1.3.1 MARKETS COVERED
1.3.2 YEARS CONSIDERED FOR THE STUDY
1.4 CURRENCY
1.5 LIMITATIONS
1.6 STAKEHOLDERS

2 RESEARCH METHODOLOGY (Page No. – 22)
2.1 RESEARCH DATA
2.1.1 SECONDARY DATA
2.1.1.1 Key data from secondary sources
2.1.2 PRIMARY DATA
2.2 MARKET SIZE ESTIMATION
2.2.1 BOTTOM-UP APPROACH
2.2.2 GROWTH FORECAST
2.3 MARKET BREAKDOWN AND DATA TRIANGULATION
2.4 ASSUMPTIONS FOR THE STUDY

3 EXECUTIVE SUMMARY (Page No. – 28)

4 PREMIUM INSIGHTS (Page No. – 32)
4.1 ATTRACTIVE MARKET OPPORTUNITIES IN THE TISSUE DIAGNOSTIC MARKET
4.2 ASIA PACIFIC MARKET: BY DISEASE
4.3 TISSUE DIAGNOSTIC MARKET: GEOGRAPHIC SNAPSHOT

5 MARKET OVERVIEW (Page No. – 35)
5.1 INTRODUCTION
5.2 MARKET DYNAMICS
5.2.1 DRIVERS
5.2.1.1 Increasing incidence of cancer
5.2.1.2 Growing healthcare expenditure
5.2.1.3 Developing infrastructure for cancer diagnosis
5.2.1.4 Recommendations for cancer screening
5.2.1.5 Availability of reimbursements
5.2.2 RESTRAINTS
5.2.2.1 High degree of consolidation
5.2.3 OPPORTUNITIES
5.2.3.1 Significant opportunities in BRICS countries
5.2.3.2 Growing demand for personalized medicines
5.2.3.3 Increasing number of clinical trials pertaining to cancer drugs
5.2.4 CHALLENGES
5.2.4.1 Stringent regulatory requirements
5.2.4.2 Lack of infrastructure and low awareness in middle- and low- income countries
5.2.4.3 Availability of refurbished products
5.2.4.4 Lack of skilled professionals
5.2.4.5 Product failures and recalls
5.2.5 TRENDS
5.2.5.1 Increasing number of reagent rental agreements

6 TISSUE DIAGNOSTICS MARKET, BY PRODUCT (Page No. – 45)
6.1 INTRODUCTION
6.2 CONSUMABLES
6.2.1 ANTIBODIES
6.2.2 KITS
6.2.3 REAGENTS
6.2.4 PROBES
6.3 INSTRUMENTS
6.3.1 SLIDE-STAINING SYSTEMS
6.3.2 SCANNERS
6.3.3 TISSUE-PROCESSING SYSTEMS
6.3.4 OTHER INSTRUMENTS

7 TISSUE DIAGNOSTICS MARKET, BY TECHNOLOGY (Page No. – 55)
7.1 INTRODUCTION
7.2 IMMUNOHISTOCHEMISTRY (IHC)
7.3 IN SITU HYBRIDIZATION (ISH)
7.4 DIGITAL PATHOLOGY AND WORKFLOW MANAGEMENT
7.5 SPECIAL STAINING

8 TISSUE DIAGNOSTICS MARKET, BY DISEASE (Page No. – 61)
8.1 INTRODUCTION
8.2 BREAST CANCER
8.3 GASTRIC CANCER
8.4 LYMPHOMA
8.5 PROSTATE CANCER
8.6 NON-SMALL CELL LUNG CANCER (NSCLC)
8.7 OTHER DISEASES

9 TISSUE DIAGNOSTICS MARKET, BY END USER (Page No. – 73)
9.1 INTRODUCTION
9.2 HOSPITALS
9.3 RESEARCH LABORATORIES
9.4 PHARMACEUTICAL COMPANIES
9.5 CONTRACT RESEARCH ORGANIZATIONS
9.6 OTHER END USERS

10 TISSUE DIAGNOSTICS MARKET, BY REGION (Page No. – 78)
10.1 INTRODUCTION
10.2 NORTH AMERICA
10.2.1 US
10.2.1.1 US is expected to be dominant country-level market for tissue diagnostics
10.2.2 CANADA
10.2.2.1 High prevalence of cancer in Canada is expected to support market growth
10.3 EUROPE
10.3.1 GERMANY
10.3.1.1 Availability of reimbursements for colorectal cancer screening
10.3.2 UK
10.3.2.1 Government initiatives to drive the growth in the UK
10.3.3 FRANCE
10.3.3.1 Increasing government funding for cancer diagnosis & prevention to support the market growth
10.3.4 ITALY
10.3.4.1 High incidence of cancer to support the market growth in Italy
10.3.5 SPAIN
10.3.5.1 High incidence of chronic diseases to drive the Spanish market
10.3.6 REST OF EUROPE (ROE)
10.4 ASIA PACIFIC
10.4.1 CHINA
10.4.1.1 Increasing healthcare expenditure
10.4.2 JAPAN
10.4.2.1 Advanced healthcare infrastructure to support market growth in Japan
10.4.3 INDIA
10.4.3.1 Expanding healthcare sector in the country to drive market growth
10.4.4 REST OF ASIA PACIFIC (ROAPAC)
10.5 REST OF THE WORLD (ROW)
10.5.1 LATIN AMERICA
10.5.1.1 Increasing number of cancer screening programs to support market growth
10.5.2 MIDDLE EAST & AFRICA
10.5.2.1 Increasing incidence of cancer in the Middle East & Africa to support market growth

11 COMPETITIVE LANDSCAPE (Page No. – 123)
11.1 OVERVIEW
11.2 MARKET SHARE ANALYSIS, 2019
11.3 COMPETITIVE SCENARIO
11.3.1 PRODUCT LAUNCHES (2017–2020)
11.3.2 PRODUCT APPROVALS (2017–2020)
11.3.3 PARTNERSHIPS AND COLLABORATIONS (2017–2020)
11.3.4 ACQUISITIONS (2017–2020)
11.4 COMPETITIVE LEADERSHIP MAPPING (2018)
11.4.1 VENDOR INCLUSION CRITERIA
11.4.2 VISIONARY LEADERS
11.4.3 DYNAMIC DIFFERENTIATORS
11.4.4 EMERGING COMPANIES

12 COMPANY PROFILES (Page No. – 129)
(Business overview, Products offered, Recent developments, MNM view)*
12.1 ROCHE
12.2 DANAHER
12.3 THERMO FISHER SCIENTIFIC
12.4 ABBOTT
12.5 AGILENT TECHNOLOGIES
12.6 MERCK KGAA
12.7 SAKURA FINETEK JAPAN
12.8 ABCAM
12.9 BECTON, DICKINSON AND COMPANY (BD)
12.10 BIO SB
12.11 BIOGENEX
12.12 CELL SIGNALING TECHNOLOGY
12.13 HISTO-LINE LABORATORIES
12.14 SLEE MEDICAL GMBH
12.15 AMOS SCIENTIFIC PTY LTD
12.16 JINHUA YIDI MEDICAL APPLIANCE CO.LTD
12.17 MEDITE GMBH
12.18 CELLPATH LTD
12.19 HOLOGIC, INC.
12.20 DIPATH S.P.A.

*Business overview, Products offered, Recent developments, MNM view might not be captured in case of unlisted companies.



★調査レポート[組織診断の世界市場予測:製品別(抗体、キット、スライド染色システム、組織処理システム)、技術別(ISH、IHC、特殊染色)、疾患別(乳がん、NSCLC、リンパ腫)、エンドユーザー別(病院、研究所)] ( Tissue Diagnostics Market by Product (Antibodies, Kits, Slide Staining System, Tissue Processing System), Technology (ISH, IHC, Special Staining), Disease (Breast Cancer, NSCLC, Lymphoma), End User (Hospitals, Research Laboratories)-Global Forecast to 2025 / MD 2349) 販売に関する免責事項
[組織診断の世界市場予測:製品別(抗体、キット、スライド染色システム、組織処理システム)、技術別(ISH、IHC、特殊染色)、疾患別(乳がん、NSCLC、リンパ腫)、エンドユーザー別(病院、研究所)] ( Tissue Diagnostics Market by Product (Antibodies, Kits, Slide Staining System, Tissue Processing System), Technology (ISH, IHC, Special Staining), Disease (Breast Cancer, NSCLC, Lymphoma), End User (Hospitals, Research Laboratories)-Global Forecast to 2025 / MD 2349) についてEメールでお問い合わせ


◆H&Iグローバルリサーチ株式会社のお客様(例)◆